UCLA's Jonsson Comprehensive Cancer Center : JCCC Member Directory

Ronald Mitsuyasu, M.D.

Specialty:

Cancer/Medical Oncology

Hematology

Hematology/Oncology

Infectious Disease

General Information:

Gender:	Male
Language(s):	English

Affiliation(s):

Director, CARE Center

Professor in Residence, Department of Medicine, Hematology/Oncology

Associate Director for Clinical Programs, UCLA AIDS Institute

Member, JCCC Tumor Immunology Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Fellowship:	Hematology/Oncology, UCLA School of Medicine, 1981 - 1984
Residency:	Internal Medicine, Rush Presbyterian - St. Luke's Medical Center, 1979 - 1981
Internship:	Internal Medicine, Rush Presbyterian - St. Luke's Medical Center, 1978 - 1979
Medical Degree:	M.D., UCLA School of Medicine, 1978

Certification(s):

Medical Board Certification(s):	Internal Medicine, American Board of Internal Medicine, 1981
Professional Certification(s):	HIV Specialist, American Academy of HIV Medicine (AAHIVM)

Contact Information:

Hematology/Oncology:	(310) 206-6909 Information and patient appointments
CARE Center:	(310) 557-9680 Information and referral (310) 557-2273 [(310) 557-CARE] Patient appointments
Email:	rmitsuya@mednet.ucla.edu
Website:	http://www.uclacarecenter.org

Scientific Interest(s):

Dr. Ronald Mitsuyasu has conducted research investigating new treatments for HIV and HIV associated malignancies since 1974. He is the director of the UCLA Center for Clinical AIDS Research and Education and has been involved in clinical trials of both antiretroviral drugs as well as immune-based therapies for HIV and complications of HIV. He is the group chair of the National Cancer Institute-sponsored AIDS Malignancy Consortium and conducts clinical trials for Kaposi's sarcoma, non-Hodgkin's lymphoma, anal cancer and anal and cervical precancerous lesions. He has and continues to be a major investigator of the role of Interleukin-2 and other cytokines and vaccines as treatment in HIV. He is a pioneer in the clinical evaluation of gene therapy for HIV and is principal investigator for an international Phase III gene therapy study, which is the first of its kind. He has clinical research experience and a background in hematology/oncology as well as in immunology and immunotherapeutics.

Selected Cancer-Related Publications:

Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Von Roenn J, Dezube BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R; AIDS Malignancy Consortium. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010 Apr 15;115(15):3008-16. Epub 2009 Dec 18.

Chiao EY, Dezube BJ, Krown SE, Wachsman W, Brock MV, Giordano TP, Mitsuyasu R, Pantanowitz L. Time for oncologists to opt in for routine opt-out HIV testing? JAMA. 2010 Jul 21;304(3):334-9.

Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari J, Becker S, Thornton L, Akil B, Khanlou H, Finlayson R, McFarlane R, Smith DE, Garsia R, Ma D, Law M, Murray JM, von Kalle C, Ely JA, Patino SM, Knop AE, Wong P, Todd AV, Haughton M, Fuery C, Macpherson JL, Symonds GP, Evans LA, Pond SM, Cooper DA. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med. 2009 Mar;15(3):285-92. Epub 2009 Feb 15.

INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009 Oct 15;361(16):1548-59.

Stapleton JT, Chaloner K, Zhang J, Klinzman D, Souza IE, Xiang J, Landay A, Fahey J, Pollard R, Mitsuyasu R. GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS. 2009 Mar 13;23(5):605-10.